BG104059A - Лечение на диабет с росиглитазон и инсулин - Google Patents

Лечение на диабет с росиглитазон и инсулин

Info

Publication number
BG104059A
BG104059A BG104059A BG10405900A BG104059A BG 104059 A BG104059 A BG 104059A BG 104059 A BG104059 A BG 104059A BG 10405900 A BG10405900 A BG 10405900A BG 104059 A BG104059 A BG 104059A
Authority
BG
Bulgaria
Prior art keywords
rosiglytazone
insulin
diabetes treatment
treatment
nontoxic
Prior art date
Application number
BG104059A
Other languages
English (en)
Inventor
Stephen Smith
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG104059A publication Critical patent/BG104059A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретението се отнася до метод за лечение на захарен диабет и свързаните с него състояния при бозайници. Методът се състои в прилагане на ефективно, нетоксично и фармацевтично приемливо количество от росиглитазон и инсулин.
BG104059A 1997-06-18 2000-01-06 Лечение на диабет с росиглитазон и инсулин BG104059A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
PCT/EP1998/003692 WO1998057636A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with rosiglitazone and insulin

Publications (1)

Publication Number Publication Date
BG104059A true BG104059A (bg) 2000-10-31

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104059A BG104059A (bg) 1997-06-18 2000-01-06 Лечение на диабет с росиглитазон и инсулин

Country Status (30)

Country Link
EP (1) EP0999837A1 (bg)
JP (1) JP2002504138A (bg)
KR (1) KR20010013843A (bg)
CN (1) CN1133431C (bg)
AP (1) AP1287A (bg)
AR (2) AR015894A1 (bg)
AU (1) AU8216398A (bg)
BG (1) BG104059A (bg)
BR (1) BR9810444A (bg)
CA (1) CA2294141A1 (bg)
CO (1) CO4940454A1 (bg)
DZ (1) DZ2521A1 (bg)
EA (1) EA004800B1 (bg)
GB (1) GB9712866D0 (bg)
HU (1) HUP0003260A3 (bg)
ID (1) ID23951A (bg)
IL (1) IL133143A0 (bg)
IN (1) IN189723B (bg)
MA (1) MA26511A1 (bg)
NO (1) NO996265L (bg)
OA (1) OA11517A (bg)
PE (1) PE104499A1 (bg)
PL (1) PL343123A1 (bg)
SK (1) SK179399A3 (bg)
TR (1) TR199903095T2 (bg)
TW (1) TW587937B (bg)
UA (1) UA70299C2 (bg)
UY (1) UY25050A1 (bg)
WO (1) WO1998057636A1 (bg)
ZA (1) ZA985237B (bg)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DZ3155A1 (fr) 1999-04-23 2000-11-02 Smithkline Beecham Plc Nouvelle composition pharmaceutique.
DK1133312T3 (da) * 1999-06-21 2008-01-02 Lilly Co Eli Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
BR0316091A (pt) * 2002-11-08 2005-09-27 Hoffmann La Roche Compostos, processo para a manufatura dos mesmos, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(a) e/ou ppar(y) e/ou utilização dos mesmos
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228260B1 (en) * 1993-09-15 2013-02-28 Daiichi Sankyo Company Pharmaceutical compositions to treat impaired glucose tolerance
CN1192683A (zh) * 1995-08-10 1998-09-09 沃尼尔·朗伯公司 减少非胰岛素依赖型糖尿病患者外源性胰岛素给药量的方法
DK0859608T3 (da) * 1995-09-18 2004-06-14 Ligand Pharm Inc Behandling af NIDDM med RXR-agonister

Also Published As

Publication number Publication date
AP9901718A0 (en) 1999-12-31
PE104499A1 (es) 2000-01-13
CN1260715A (zh) 2000-07-19
IN189723B (bg) 2003-04-19
AR015894A1 (es) 2001-05-30
CN1133431C (zh) 2004-01-07
KR20010013843A (ko) 2001-02-26
OA11517A (en) 2004-02-04
IL133143A0 (en) 2001-03-19
AR012997A1 (es) 2000-11-22
MA26511A1 (fr) 2004-12-20
UA70299C2 (en) 2004-10-15
EA200000042A1 (ru) 2000-08-28
SK179399A3 (en) 2000-11-07
HUP0003260A2 (hu) 2001-05-28
AU8216398A (en) 1999-01-04
ID23951A (id) 2000-06-08
EA004800B1 (ru) 2004-08-26
CO4940454A1 (es) 2000-07-24
EP0999837A1 (en) 2000-05-17
JP2002504138A (ja) 2002-02-05
BR9810444A (pt) 2000-09-05
DZ2521A1 (fr) 2003-02-08
GB9712866D0 (en) 1997-08-20
TW587937B (en) 2004-05-21
ZA985237B (en) 2000-02-17
CA2294141A1 (en) 1998-12-23
UY25050A1 (es) 2000-09-29
AP1287A (en) 2004-06-26
NO996265D0 (no) 1999-12-17
HUP0003260A3 (en) 2001-12-28
WO1998057636A1 (en) 1998-12-23
NO996265L (no) 1999-12-17
PL343123A1 (en) 2001-07-30
TR199903095T2 (xx) 2000-08-21

Similar Documents

Publication Publication Date Title
BG104060A (bg) Комбинация от тиазолидиндион и метформин, състав и използване
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
AU2373400A (en) Shelf-stable formulation of glucagon-like peptide-1
BG104059A (bg) Лечение на диабет с росиглитазон и инсулин
AU5456598A (en) Insulin delivery enhanced by coached breathing
EP0647133A4 (en) COMPOSITIONS AND METHODS FOR IMPROVED DRUG DELIVERY.
AU2272097A (en) Drug delivery compositions suitable for intravenous injection
HK1070589A1 (en) Prolanged delivery of peptides
MY129220A (en) "use of glp-1 analogs and derivatives administered peripherally in regulation of obesity"
IL199364A0 (en) Use of pyy for preparation of a medicament for modification of feeding behavior
ZA975065B (en) Delivery needle.
WO2000016797A3 (en) Use of glp-1 or analogs in treatment of stroke
BG103740A (bg) Фитостеролен състав за предпазване от болестта наалцхаймер
CA2284482A1 (en) Treatment of cardiomyopathy
AU4714393A (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
BG104135A (bg) Комбинация от тиазолидиндион, средство увеличаващо секрецията на инсулин и бигуанид, фармацевтичен състав и използване
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
UA42819C2 (uk) Ін`єкційний та інфузійний розчин, що містить енрофлокcацин
EP0683668A4 (en) PREPARATIONS AND METHODS FOR TRANSDERMAL DRUG ADMINISTRATION.
BG104062A (bg) Лечение на диабет с тиазолидиндион, инсулинов секретагог и инхибитор на алфа-глюкозидазата
BG104058A (bg) Комбинация от тиазолидиндион и сулфонилуреа, състав и използване
BG104139A (bg) Лечение на диабет с тиазолидиндион и сулфонилурея
AU8019898A (en) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome
WO1999053064A3 (en) Methods of delivering glp-1
IL143088A0 (en) A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method